Concepts (171)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma | 10 | 2021 | 56 | 2.550 |
Why?
|
| Bone Neoplasms | 12 | 2020 | 104 | 2.490 |
Why?
|
| Soft Tissue Neoplasms | 8 | 2021 | 35 | 2.220 |
Why?
|
| Brachytherapy | 2 | 2018 | 22 | 1.050 |
Why?
|
| Orthopedics | 2 | 2019 | 93 | 0.760 |
Why?
|
| Spinal Neoplasms | 1 | 2019 | 20 | 0.690 |
Why?
|
| Spine | 1 | 2019 | 38 | 0.690 |
Why?
|
| Incidental Findings | 1 | 2019 | 26 | 0.680 |
Why?
|
| Joint Instability | 2 | 2019 | 70 | 0.670 |
Why?
|
| Diffusion of Innovation | 1 | 2018 | 29 | 0.650 |
Why?
|
| Interdisciplinary Communication | 1 | 2018 | 53 | 0.640 |
Why?
|
| Internship and Residency | 2 | 2019 | 283 | 0.630 |
Why?
|
| Radiation Dosage | 1 | 2018 | 72 | 0.630 |
Why?
|
| Humerus | 2 | 2013 | 29 | 0.620 |
Why?
|
| Chondrosarcoma | 4 | 2020 | 7 | 0.600 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 104 | 0.590 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2021 | 337 | 0.580 |
Why?
|
| Lipoma | 1 | 2015 | 8 | 0.530 |
Why?
|
| Tendon Injuries | 1 | 2014 | 36 | 0.490 |
Why?
|
| Humans | 31 | 2021 | 29220 | 0.480 |
Why?
|
| Osteochondroma | 1 | 2013 | 2 | 0.460 |
Why?
|
| Giant Cell Tumors | 1 | 2013 | 4 | 0.460 |
Why?
|
| Limb Salvage | 7 | 2021 | 24 | 0.460 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2020 | 1219 | 0.450 |
Why?
|
| Tendons | 1 | 2013 | 57 | 0.440 |
Why?
|
| Wrist Joint | 1 | 2013 | 47 | 0.440 |
Why?
|
| Cell Proliferation | 2 | 2020 | 573 | 0.420 |
Why?
|
| Retrospective Studies | 12 | 2021 | 3122 | 0.390 |
Why?
|
| Antimicrobial Cationic Peptides | 2 | 2020 | 14 | 0.380 |
Why?
|
| Middle Aged | 17 | 2020 | 10872 | 0.380 |
Why?
|
| Radiography | 4 | 2016 | 353 | 0.360 |
Why?
|
| Neoplastic Stem Cells | 2 | 2020 | 90 | 0.360 |
Why?
|
| Adult | 15 | 2020 | 8468 | 0.350 |
Why?
|
| Female | 18 | 2020 | 18241 | 0.280 |
Why?
|
| Femoral Neoplasms | 2 | 2010 | 4 | 0.280 |
Why?
|
| Male | 15 | 2018 | 17876 | 0.270 |
Why?
|
| Aged | 13 | 2018 | 9515 | 0.270 |
Why?
|
| Predictive Value of Tests | 3 | 2018 | 788 | 0.270 |
Why?
|
| Neoplasm, Residual | 4 | 2016 | 23 | 0.270 |
Why?
|
| Physical Examination | 3 | 2013 | 82 | 0.260 |
Why?
|
| Treatment Outcome | 7 | 2018 | 3108 | 0.250 |
Why?
|
| Fibrous Dysplasia of Bone | 2 | 2014 | 2 | 0.250 |
Why?
|
| Biopsy | 3 | 2013 | 241 | 0.250 |
Why?
|
| Young Adult | 8 | 2020 | 2413 | 0.240 |
Why?
|
| Adolescent | 8 | 2016 | 3265 | 0.220 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2018 | 68 | 0.220 |
Why?
|
| Biopsy, Needle | 2 | 2016 | 89 | 0.220 |
Why?
|
| Aged, 80 and over | 8 | 2016 | 3728 | 0.220 |
Why?
|
| Fractures, Spontaneous | 2 | 2019 | 14 | 0.210 |
Why?
|
| Amyloidosis | 1 | 2021 | 10 | 0.210 |
Why?
|
| Joint Diseases | 1 | 2021 | 33 | 0.200 |
Why?
|
| Orthopedic Procedures | 2 | 2019 | 92 | 0.200 |
Why?
|
| Tibia | 2 | 2014 | 56 | 0.200 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2010 | 5 | 0.190 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 5 | 0.190 |
Why?
|
| Office Visits | 1 | 2010 | 71 | 0.180 |
Why?
|
| Bone Transplantation | 2 | 2016 | 47 | 0.180 |
Why?
|
| Subcutaneous Fat | 1 | 2020 | 42 | 0.180 |
Why?
|
| Ambulatory Care | 1 | 2010 | 97 | 0.180 |
Why?
|
| Mycetoma | 1 | 2009 | 1 | 0.180 |
Why?
|
| Leg Dermatoses | 1 | 2009 | 2 | 0.180 |
Why?
|
| Foot Diseases | 1 | 2009 | 7 | 0.180 |
Why?
|
| Ulcer | 1 | 2009 | 3 | 0.170 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2009 | 15 | 0.170 |
Why?
|
| Lower Extremity | 1 | 2020 | 94 | 0.170 |
Why?
|
| Knee Injuries | 1 | 2019 | 39 | 0.170 |
Why?
|
| Palliative Care | 1 | 2019 | 47 | 0.170 |
Why?
|
| Neurosurgical Procedures | 1 | 2019 | 98 | 0.160 |
Why?
|
| Combined Modality Therapy | 3 | 2016 | 525 | 0.160 |
Why?
|
| Patient Care Team | 1 | 2019 | 124 | 0.160 |
Why?
|
| Specialties, Surgical | 1 | 2018 | 24 | 0.160 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2018 | 11 | 0.160 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2009 | 142 | 0.160 |
Why?
|
| Athletic Injuries | 1 | 2019 | 77 | 0.160 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2019 | 84 | 0.150 |
Why?
|
| Surgical Wound Infection | 1 | 2018 | 74 | 0.150 |
Why?
|
| Pediatrics | 1 | 2018 | 132 | 0.140 |
Why?
|
| Range of Motion, Articular | 2 | 2013 | 177 | 0.140 |
Why?
|
| Wound Healing | 1 | 2018 | 182 | 0.140 |
Why?
|
| Tarsal Bones | 1 | 2016 | 5 | 0.140 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2016 | 6 | 0.140 |
Why?
|
| Prognosis | 5 | 2015 | 1363 | 0.140 |
Why?
|
| Postoperative Complications | 2 | 2020 | 670 | 0.140 |
Why?
|
| Arthrodesis | 1 | 2016 | 21 | 0.140 |
Why?
|
| Pain | 1 | 2009 | 282 | 0.140 |
Why?
|
| Diagnosis, Differential | 4 | 2014 | 493 | 0.140 |
Why?
|
| Shoulder Joint | 1 | 2008 | 123 | 0.140 |
Why?
|
| Risk Assessment | 2 | 2018 | 1313 | 0.130 |
Why?
|
| Time Factors | 2 | 2018 | 2003 | 0.130 |
Why?
|
| Granuloma, Foreign-Body | 1 | 2014 | 7 | 0.130 |
Why?
|
| Osteitis Deformans | 1 | 2014 | 2 | 0.130 |
Why?
|
| Enchondromatosis | 1 | 2014 | 3 | 0.130 |
Why?
|
| Exostoses, Multiple Hereditary | 1 | 2014 | 2 | 0.130 |
Why?
|
| Sutures | 1 | 2014 | 19 | 0.120 |
Why?
|
| Risk Factors | 2 | 2018 | 3550 | 0.120 |
Why?
|
| United States | 2 | 2019 | 3648 | 0.110 |
Why?
|
| Extremities | 3 | 2021 | 48 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 401 | 0.110 |
Why?
|
| Wound Infection | 1 | 2012 | 11 | 0.110 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2012 | 30 | 0.110 |
Why?
|
| Recovery of Function | 1 | 2013 | 190 | 0.100 |
Why?
|
| Child | 4 | 2010 | 2221 | 0.100 |
Why?
|
| Cell Survival | 2 | 2020 | 272 | 0.090 |
Why?
|
| Neoplasm Staging | 3 | 2016 | 437 | 0.090 |
Why?
|
| Artificial Limbs | 1 | 2008 | 2 | 0.080 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 681 | 0.080 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2008 | 48 | 0.080 |
Why?
|
| Reoperation | 2 | 2013 | 203 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 2114 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2016 | 163 | 0.060 |
Why?
|
| Femur | 2 | 2014 | 67 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 281 | 0.050 |
Why?
|
| beta 2-Microglobulin | 1 | 2021 | 6 | 0.050 |
Why?
|
| Amyloid | 1 | 2021 | 17 | 0.050 |
Why?
|
| Curettage | 1 | 2010 | 9 | 0.050 |
Why?
|
| Antigens, Surface | 1 | 2020 | 19 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 1 | 2020 | 22 | 0.050 |
Why?
|
| Spheroids, Cellular | 1 | 2020 | 29 | 0.050 |
Why?
|
| Retinal Dehydrogenase | 1 | 2020 | 2 | 0.050 |
Why?
|
| Florida | 1 | 2010 | 33 | 0.050 |
Why?
|
| Necrosis | 1 | 2010 | 53 | 0.050 |
Why?
|
| Chromatin | 1 | 2020 | 19 | 0.050 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 98 | 0.040 |
Why?
|
| Itraconazole | 1 | 2009 | 6 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 871 | 0.040 |
Why?
|
| Periosteum | 1 | 2009 | 9 | 0.040 |
Why?
|
| Toes | 1 | 2009 | 16 | 0.040 |
Why?
|
| Osteosarcoma | 1 | 2009 | 12 | 0.040 |
Why?
|
| Hemangioma | 1 | 2009 | 18 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2009 | 34 | 0.040 |
Why?
|
| Arthrography | 1 | 2009 | 9 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 249 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2021 | 261 | 0.040 |
Why?
|
| Fluoroscopy | 1 | 2008 | 37 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 641 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 116 | 0.040 |
Why?
|
| Prosthesis Failure | 1 | 2008 | 43 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2008 | 113 | 0.040 |
Why?
|
| Prostheses and Implants | 1 | 2008 | 41 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 726 | 0.040 |
Why?
|
| Knee Joint | 1 | 2009 | 129 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2008 | 440 | 0.040 |
Why?
|
| Comorbidity | 1 | 2009 | 546 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2009 | 365 | 0.040 |
Why?
|
| Fracture Fixation, Internal | 1 | 2008 | 117 | 0.040 |
Why?
|
| Ifosfamide | 1 | 2016 | 4 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 638 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2019 | 307 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2016 | 98 | 0.040 |
Why?
|
| Rare Diseases | 1 | 2016 | 20 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 710 | 0.040 |
Why?
|
| Cisplatin | 1 | 2016 | 69 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2016 | 56 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2016 | 55 | 0.040 |
Why?
|
| Pregnancy | 1 | 2009 | 816 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2016 | 172 | 0.030 |
Why?
|
| Skin Transplantation | 1 | 2015 | 50 | 0.030 |
Why?
|
| Ilium | 1 | 2014 | 13 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 519 | 0.030 |
Why?
|
| Surgical Flaps | 1 | 2015 | 69 | 0.030 |
Why?
|
| Pelvic Bones | 1 | 2014 | 31 | 0.030 |
Why?
|
| Survival Rate | 1 | 2016 | 795 | 0.030 |
Why?
|
| Ribs | 1 | 2014 | 40 | 0.030 |
Why?
|
| Calcinosis | 1 | 2014 | 143 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2013 | 60 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 384 | 0.020 |
Why?
|
| Hip Prosthesis | 1 | 2008 | 12 | 0.020 |
Why?
|
| Prosthesis Implantation | 1 | 2008 | 35 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2008 | 199 | 0.020 |
Why?
|
| Walking | 1 | 2008 | 178 | 0.020 |
Why?
|
| Age Factors | 1 | 2008 | 1110 | 0.020 |
Why?
|